All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.
Introducing
Now you can personalise
your AML Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe AML Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the AML Hub cannot guarantee the accuracy of translated content. The AML Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The AML Hub is an independent medical education platform, sponsored by Daiichi Sankyo, Jazz Pharmaceuticals, Johnson & Johnson, Kura Oncology, Roche, Syndax and Thermo Fisher, and has been supported through a grant from Bristol Myers Squibb. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Bookmark this article
The virtual AML Hub Satellite Symposium at the 46th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) brought together an international panel of experts to discuss how measurable residual disease (MRD) impacts outcome of stem cell transplantation in AML, now and in the future. Professor Jacqueline Cloos, Amsterdam University Medical Center, Amsterdam, NL, presented the topic ‘Challenges in MRD measurement by multiparameter flow cytometry in AML.’
Following a brief overview of the techniques used to assess MRD in AML, Professor Jacqueline Cloos focuses her presentation on the technical aspects of multiparameter flow cytometry, one of the most commonly used methods for MRD detection. She describes the different approaches for multiparameter flow cytometry MRD assessment and the limitations of this technique. She also reports on the European LeukemiaNet (ELN) Working Party recommendations for MRD measurement by multiparameter flow cytometry in AML.
Welcome to the AML Hub Satellite Symposium.
Please take a moment to complete the survey and answer the following question to help us gauge your current understanding of MRD assessment by flow cytometry in AML.
Your opinion matters
Subscribe to get the best content related to AML delivered to your inbox